imatinib
Other information you can find at Online Pharmacy in Ontario.
The anti-cancer drug called 'Sunitinib' is being developed by Pfizer Inc. It is used to treat gastrointestinal stromal tumours – a type of tumours that grow in the stomach, intestine or esophagus, the tube that connects the throat with the stomach in people.
The new drug is one of a family of new and powerful anti-cancer drugs called tyrosine-kinase inhibitors, which target key molecular pathways thought to encourage tumour growth. Other drugs in this family include imatinib, better known as Gleevec, and dasatinib (Sprycel), health portal HealthDay reported.
Scientists led by Ming Hui Chen, an assistant professor of medicine at Harvard Medical School and a cardiologist at Children's Hospital, Boston, studied 75 patients with stomach tumours that had not responded to the standard therapy with Gleevec.
The patients had taken part in a trial studying the efficacy of Sunitinib. The researchers looked back at the medical records of the studied patients, noting those who died from heart disease or had suffered heart attacks or congestive heart failure.
They also looked at the effect of Sunitinib on the heart's ability to pump blood and on blood pressure. Chen's team found that eight patients given repeated cycles of Sunitinib had cardiovascular events.
Two had heart attacks, and six had heart failure. Of the 36 patients given the approved dose of Sunitinib, 10 had a 10 percent or more reduction in the ability of their heart to pump blood, and seven had a 15 percent or more reduction in heart function.
In addition, Sunitinib was associated with increases in blood pressure, with a total of 35 (47 percent) of the patients developing hypertension, the scientists said in their findings published in the Dec 15 issue of The Lancet.
However, these effects were not permanent: When Sunitinib treatment was stopped and patients began therapy to ease heart problems, levels of heart failure and heart functioning improved, they said.
In addition, Chen's team found that Sunitinib triggered heart cells' damage and death when they experimented that drug on mice and rat heart cells.
The drug maker Pfizer Inc. agreed that these heart risks do exist. However, they added that the cardiovascular events were medically manageable in most patients.
Last news oncholesterol
-
Ancient and modern: First science academy is 350 years old
Other Sciences / Other
5 hours ago |
4 / 5 (2) |
1From its classical pillars and porticoed entrance to its oil paintings of great men and women and archives that include the death mask of Sir Isaac Newton, history sits grandly on the Royal Society.
-
UN climate panel based claims on student essay: report
Space & Earth / Environment
5 hours ago |
4.5 / 5 (2) |
1The UN climate change panel based claims about ice disappearing from the world's mountain peaks on a student essay and an article in a mountaineering magazine, a British newspaper reported Sunday.
-
Fears Australian piracy case could shut off net
Technology / Internet
5 hours ago |
5 / 5 (1) |
0Australian Internet rights groups fear a piracy court case could force Internet Service Providers (ISPs) to become “copyright cops” and cut web access to customers who make illegal downloads.
-
Obama pushes nuclear energy to boost climate bill
Technology / Energy
1hour ago |
not rated yet |
0(AP) — President Barack Obama is endorsing nuclear energy like never before, trying to win over Republicans and moderate Democrats on climate and energy legislation.
-
Coral in Florida Keys suffers lethal hit from cold
Space & Earth / Environment
18 hours ago |
5 / 5 (6) |
3Bitter cold this month may have wiped out many of the shallow water corals in the Keys.
-
Books pulled from Amazon.com in pricing dispute
Technology / Internet
14 hours ago |
4 / 5 (1) |
0(AP) — New copies of Hilary Mantel's “Wolf Hall,” Andrew Young's “The Politician” and other books published by Macmillan were unavailable Saturday on Amazon.com, a drastic step in the ongoing dispute over …
-
iPad neat, but I'm waiting for ver. 2.0
Electronics / Consumer & Gadgets
21 hours ago |
2.7 / 5 (3) |
3After playing with Apple's iPad at its press debut Wednesday, I want to buy one — just not yet. One of technology's truisms is that version 2.0 is almost always much better than version 1.0. So it's usually …
-
Farmers mainly to blame for deforestation in the Amazon
Space & Earth / Environment
17 hours ago |
5 / 5 (1) |
2(PhysOrg.com) — Small-scale farmers who lease land from the Brazilian government are very much responsible for deforestation in the Brazilian state of Rondonia in the Amazon area. In most areas with agrarian projects, more …
-
News Corp. in 500-million-dollar settlement with Valassis
Technology / Business
13 hours ago |
3 / 5 (2) |
1News Corp. said Saturday it had reached a 500-million-dollar settlement over lawsuits filed by Valassis Communications Inc. against a division of Rupert Murdoch's entertainment and media giant.
-
California to vote on naming Apollo 11's garbage a historical resource
Space & Earth / Space Exploration
19 hours ago |
5 / 5 (1) |
0When the Apollo 11 astronauts blasted off from the moon, they left behind not just the small steps of men but a giant pile of equipment and junk for all of mankind.
Washington, Jan 12 (ANI): A growth factor, called PDGFR, which is a common target of cancer drugs, has been found to play an important role in the heart’s response to stress, according to researchers at The University of Texas M. D. Anderson Cancer Center.
In many cancers, the body makes too much platelet-derived growth factor receptor (PDGFR), a type of protein that controls cell growth, allowing cancer cells to increase uncontrollably.
Several chemotherapy agents, including Sutent(r) (sunitinib), Nexavar(r) (sorafenib) and Gleevec(r) (imatinib), work by targeting and inhibiting PDGFR.
This slows the growth of cancer – as well as angiogenesis, which is the growth of new blood vessels.
“Recently, some of these targeted anti-cancer drugs have been associated with heart failure. But the role of PDGFR signaling in the heart has been largely unexplored until now,” said Dr. Aarif Khakoo.
In the study, the researchers showed that, while PDGFR-inhibiting agents may slow the growth of cancer cells, they also may impair the heart’s ability to respond to stress.
Since these agents also often cause elevated blood pressure, this causes a double bind of added stress to the heart and lessened capacity to deal with this stress.
Using special laboratory mice with limited cardiac PDGFR and mice with normal PDGFR signaling, researchers performed transverse aortic constriction (TAC)- a procedure widely used to study heart disease in which a band is placed at the aortic arch, resulting in acute pressure overload.
And they found that the mice with limited PDGFR had heart failure.
“We showed that cardiomyocyte PDGFR expression and activation in heart muscle cells rises dramatically in response to pressure overload stress. Furthermore, we showed that knockout of PDGFR in heart muscle results in cardiac dysfunction, heart failure and a marked defect in stress-induced cardiac angiogenesis,” said Khakoo.
They also demonstrated that PDGFR signalling is crucial in the creation of new blood vessels that help the heart respond to stress.
The study opens the door to studying additional effects of PDGFR-inhibiting drugs on the heart, as well as ways to prevent damage to the heart.
“Patients with pre-existing heart disease may be at increased risk for cardiomyopathy and heart failure associated with these drugs. If we can confirm this, it might help develop a tool to determine the individual risk for cancer patients being considered for treatment with PDGFR inhibitors and to develop strategies to prevent heart damage,” said Khakoo.
The study has been published in the Journal of Clinical Investigation. (ANI)
Buy Lipitor at Online Pharmacy in Thousand Oaks.
